Cardiol Therapeutics (TSE: CRDL- OTCQX: CRTPF) CEO David Elsley joined Steve Darling from Proactive to share news the company has announced topline results from a Phase I single and multiple ascending dose clinical trial of CardiolRx.
Elsley said the study was a placebo-controlled, double-blind study and consisted of 52 subjects ranging in age split into two groups. The study demonstrated that CardiolRx was safe and generally well-tolerated at all dose levels, with no serious adverse events reported in the study. Fifty-one of the 52 enrolled subjects completed all requirements of the protocol.